Skip to content

The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04885582
Enrollment
80
Registered
2021-05-13
Start date
2017-05-10
Completion date
2020-05-20
Last updated
2021-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HLA Antigens, Liver Transplant; Complications

Keywords

Liver Transplant, Complications, HLA, biliary fistula, biliary stricture

Brief summary

Liver transplantation has become the accepted treatment option for advanced liver failure in recent years. In addition to the increase in the number of centers performing transplant and the decrease in complication rates depending on the experience gained, the most common biliary complications did not improve at the desired level. For this reason, studies in this field are frequent today. The structural complexities of HLA antigens have been the subject of investigation in recent years. With the development of DNA and RNA amplification methods; It is increasingly difficult for physicians to keep up with the increasing burden of knowledge regarding the genetic aspects of these antigens. Concrete benefits of this gene complex, which has been investigated in various fields and preserves its mystery, have not been determined in liver transplant patients. However, there are publications showing its connection with the bile epithelium in liver transplantation and its relationship with the disappearing bile duct syndrome. In this study, our aim is to explain whether the bile duct complications, which appear like a continuous wall and can lead to frightening pictures, are related to HLA tissue compatibility.

Interventions

OTHERHLA antigen results

HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.

Sponsors

Inonu University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* patients with liver transplantation and tested for HLA antigen (recipient - donor)

Exclusion criteria

* patients who died early Patients whose HLA antigen is not checked

Design outcomes

Primary

MeasureTime frameDescription
Bliary complications2 yearsBiliary fistüla, biliary stenosis

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026